Venetoclax plus Cytarabine and Azacitidine in Relapsed/Refractory AML: An Open-Label, Single-arm, Phase 2 Study.

The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML.

Source: European Journal of Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Liangshun You, Yi Liu, Wenyuan Mai, Wanzhuo Xie, De Zhou, Liping Mao, Lili Chen, Xinping Zhou, Liya Ma, Xiaolong Zheng, Juying Wei, Yinjun Lou, Xingnong Ye, Hongyan Tong, Jie Jin, Haitao Meng Tags: Original Research Source Type: research